Biotech stocks underperform S&P 500 by 5% in 6 months

Market overview

Investors anticipate stricter FDA policies post-Makary, reducing valuations for biotech firms reliant on speedy approvals. A broad sell-off in biotech ETFs is likely if approval delays materialize.

price prediction market

Implied probability (Yes)

60%

Source: user-generated

More price markets

• X-energy stock to rise 20% within 6 months — 55% Yes
• Byzantine artifacts auction prices rise 20% within a year — 55% Yes
• US AI stock ETFs underperform S&P 500 by year-end 2026 — 58% Yes
• WuXi AppTec drops 20% from peak — 60% Yes
• OpenAI's stock rises 12% within 90 days of Codex mobile launch — 65% Yes
• Coinbase stock exceeds $300 within 30 days — 70% Yes
• Air New Zealand’s share price rises 15% on takeover speculation by 2026-06-30 — 65% Yes
• SK Hynix stock outperforms Samsung’s memory segment in 2026 — 68% Yes

Browse all price markets →